Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies
Successful cancer immunotherapies rely on a replete and functional immune compartment. Within the immune compartment, T cells are often the effector arm of immune-based strategies due to their potent cytotoxic capabilities. However, many tumors have evolved a variety of mechanisms to evade T cell-me...
Guardado en:
Autores principales: | Jessica Waibl Polania, Emily C. Lerner, Daniel S. Wilkinson, Alexandra Hoyt-Miggelbrink, Peter E. Fecci |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/808b5813dcf74fa597cb5e25097d8f85 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
por: Amy J. Petty, et al.
Publicado: (2021) -
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
por: Christopher Sloas, et al.
Publicado: (2021) -
Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?
por: Léonce Kouakanou, et al.
Publicado: (2021) -
Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
por: Mehran Bahraini, et al.
Publicado: (2021) -
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
por: Hawkins ER, et al.
Publicado: (2021)